Host-Directed Therapy in Nontuberculous Mycobacterial Pulmonary Disease
Clinics in Chest Medicine · 2023-12 · 44 (4) · 839-845
DOI: 10.1016/j.ccm.2023.07.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics in Chest Medicine, 2023-12. Verfasst von Ifeanyichukwu U Anidi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Division, National Heart, Lung and Blood Institute, National Institutes of Health, 33 North Drive, Room 1W10A, Bethesda, MD 20892, USA. Ele…. Hauptthemen laut MEDLINE: Mycobacterium Infections, Nontuberculous, Lung Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Heart, Lung, and Blood Institute, NHLBI Division of Intramural Research.
Abstract (Originalsprache)
Standard treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD) infection involves a multi-drug antimicrobial regimen for at least 12 months. The length, complexity, and side effect profile of antibiotic therapy for NTM-PD pose significant difficulties for maintaining patient adherence. Furthermore, physician adherence to NTM guidelines suffers for similar reasons to the extent that a study evaluating treatment approaches across multiple specialties found that only 13% of antibiotic regimens met ATS/IDSA guidelines. For this reason, a great need exists for therapy that augments the current armamentarium of antimicrobial chemotherapeutics or provides an alternative approach for decreasing host mycobacterial burden. As our knowledge of the mechanisms driving protective responses to NTM-PD infections by mammalian hosts expand, these processes provide novel therapeutic targets. These agents, which are commonly referred to as host-directed therapies (HDTs) have the potential of providing the much-needed boost to the nontuberculous mycobacterial therapeutic pipeline. In this review, we will focus on translational research and clinical trial data that detail the creation of therapeutic modalities developed to improve host mechanical protection and immunologic responses to PNTM infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Division, National Heart, Lung and Blood Institute, National Institutes of Health, 33 North Drive, Room 1W10A, Bethesda, MD 20892, USA. Electronic address: ifeanyichukwu.anidi@nih.gov.
- Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina School of Medicine, 125 Mason Farm Road, CB#7248, 7214 Marsico Hall, Chapel Hill, NC 27599-7248, USA.
Förderung
- Intramural NIH HHS
- National Heart, Lung, and Blood Institute
- NHLBI Division of Intramural Research
Zitieren
APA
Anidi, I. U., & Olivier, K. N. (2023). Host-Directed Therapy in Nontuberculous Mycobacterial Pulmonary Disease. Clinics in Chest Medicine, 44(4), 839-845. https://doi.org/10.1016/j.ccm.2023.07.004
Vancouver
Anidi IU, Olivier KN. Host-Directed Therapy in Nontuberculous Mycobacterial Pulmonary Disease. Clinics in Chest Medicine. 2023;44(4):839-845. doi:10.1016/j.ccm.2023.07.004
BibTeX
@article{Anidi2023,
author = {Anidi, Ifeanyichukwu U and Olivier, Kenneth N},
title = {Host-Directed Therapy in Nontuberculous Mycobacterial Pulmonary Disease},
journal = {Clinics in Chest Medicine},
year = {2023},
volume = {44},
number = {4},
pages = {839--845},
doi = {10.1016/j.ccm.2023.07.004}
}
EUVIMED